Administration of recombinant IL-18 synergized with the costimulatory ligand B7.1 to induce melanoma regression [119] and early immunotherapies based on IL-18 have shown efficacy and the ability to generate antitumor responses. The gene discussed is IL18; the disease is melanoma.